Psy147 - Availability and Reimbursement of Orphan Drugs in the Czech Republic

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.2721
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Reimbursement of Orphan Drugs: The Pompe and Fabry Case in the Netherlands

Orphanet Journal of Rare Diseases
MedicineGeneticsPharmacology
2014English

Reimbursement of Orphan Drugs in Belgium: What (Else) Matters?

Orphanet Journal of Rare Diseases
MedicineGeneticsPharmacology
2014English

Pricing and Reimbursement of Orphan Drugs: The Need for More Transparency

Orphanet Journal of Rare Diseases
MedicineGeneticsPharmacology
2011English

Reimbursement Decision Landscape for Orphan Drugs Across Six Hta Agencies

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

Regulation, Pricing of Drugs and Parallel Trade in Czech Republic

2016English

Pdb58 - Reimbursement for Type 2 Diabetes Mellitus Patients Hospitalized in a Municipal Hospital in the Czech Republic

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Czech Republic

Education at a Glance
2013English

Low Availability of Orphan Medicines in Serbia

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Midwifery in the Czech Republic

Kontakt
EnvironmentalPublic HealthPhilosophyNursingOccupational Health
2008English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy